Skip to content

Dr. Gearóid Tuohy

Autosomal-recessive retinitis pigmentosa (arRP) – a mutation (E150K) of rhodopsin may provide a CRISPR treatment with functional and structural rescue.

Researchers at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, has reported an experimental treatment using a CRISPR/Cas9 adenine base editing… Read More »Autosomal-recessive retinitis pigmentosa (arRP) – a mutation (E150K) of rhodopsin may provide a CRISPR treatment with functional and structural rescue.

Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company based in Iselin, New Jersey, USA, has announced that the UK NICE (National Institute for Health and… Read More »Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.

Korean research team provide an Artificial intelligence (AI) tool for predicting the treatment response of nAMD based on OCT biomarkers.

A team of Korean researchers have published a study using an AI-model of optical coherence tomography (OCT) image data to predict AMD treatment outcomes following… Read More »Korean research team provide an Artificial intelligence (AI) tool for predicting the treatment response of nAMD based on OCT biomarkers.

An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.

Researchers at the Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea, have outlined an increasing future burden of depressive disorders, providing… Read More »An investigation of the association between Retinitis pigmentosa (RP) and depressive disorder, including a call for practical training and methods.

The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).    

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of… Read More »The CHMP (EMA) has issued a positive opinion for the marketing authorisation of FYB203, a biosimilar candidate to Eylea (Aflibercept).    

A novel induced pluripotent stem cell model shows a mechanistic defect and potential therapy for AMD and related macular dystrophies.

Researchers at the Department of Ophthalmology, and the Center for Visual Science, University of Rochester, New York, have reported a study using induced pluripotent stem… Read More »A novel induced pluripotent stem cell model shows a mechanistic defect and potential therapy for AMD and related macular dystrophies.